250 related articles for article (PubMed ID: 25565011)
1. Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris.
Takahashi T; Asano Y; Shibata S; Nakamura K; Nakao M; Shida R; Mitsui A; Araki M; Watanabe R; Fujita H; Tada Y; Sato S
Br J Dermatol; 2015; 172(5):1458-60. PubMed ID: 25565011
[No Abstract] [Full Text] [Related]
2. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
[No Abstract] [Full Text] [Related]
3. Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.
Membrillo de Novales FJ; Ávila Jiménez A; Merino Meléndez L; Torres León J; López Soberón E; Fe Marqués A; Pérez Mochales JF
J Clin Rheumatol; 2015 Apr; 21(3):171-3. PubMed ID: 25807103
[No Abstract] [Full Text] [Related]
4. Worsening of Psoriatic Arthritis After Ustekinumab Treatment.
Onsun N; Yalcin B; Sallahoglu K; Rezvani A
Am J Ther; 2018; 25(3):e381-e382. PubMed ID: 29189317
[No Abstract] [Full Text] [Related]
5. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
6. Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination.
Haberman RH; Castillo R; Scher JU
Rheumatology (Oxford); 2021 Jul; 60(7):e225-e226. PubMed ID: 33369644
[No Abstract] [Full Text] [Related]
7. The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
Tabolli S; Giannantoni P; Paradisi A; Abeni D
Br J Dermatol; 2015 Jul; 173(1):256-8. PubMed ID: 25422080
[No Abstract] [Full Text] [Related]
8. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab.
Benzaquen M; Monnier J; Beaussault Y; Rouby F; Berbis P
Australas J Dermatol; 2017 Nov; 58(4):e270-e271. PubMed ID: 28660635
[No Abstract] [Full Text] [Related]
9. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
[TBL] [Abstract][Full Text] [Related]
10. How effective is ustekinumab in controlling psoriatic arthritis?
Bonifati C; Graceffa D
Dermatol Ther; 2016 May; 29(3):155-9. PubMed ID: 26626908
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of biologics with traditional agents in psoriasis.
Guenther LC
Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
[TBL] [Abstract][Full Text] [Related]
12. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
Borrás-Blasco J; Gracia-Perez A; Nuñez-Cornejo C; Rosique-Robles JD; Mateu-Puchades A; Casterá MD; Rubio-Fabra M
J Clin Pharm Ther; 2008 Jun; 33(3):321-5. PubMed ID: 18452420
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of Psoriasis Arthritis Taking into Account New Treatment Options].
Ryser C; Ciurea A
Praxis (Bern 1994); 2018; 107(21):1147-1153. PubMed ID: 30326810
[TBL] [Abstract][Full Text] [Related]
14. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald JM; Klufas DM; Strober BE
J Drugs Dermatol; 2015 Aug; 14(8):888-92. PubMed ID: 26267735
[TBL] [Abstract][Full Text] [Related]
15. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor-induced cutaneous leishmaniasis in patient with psoriatic arthritis and uveitis.
Hernandez Bel L; Hernández Garfella ML; Chiarri Toumit C; Valenzuela Oñate C
Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):621-622. PubMed ID: 30100239
[No Abstract] [Full Text] [Related]
17. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.
Jacobi A; Rustenbach SJ; Augustin M
Int J Dermatol; 2016 Mar; 55(3):296-302. PubMed ID: 26470689
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
Kolios AGA; Biedermann L; Weber A; Navarini AA; Meier J; Cozzio A; French LE
Br J Dermatol; 2018 Feb; 178(2):551-555. PubMed ID: 28477389
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
[TBL] [Abstract][Full Text] [Related]
20. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]